Affordable Access

Circulating diazepam-binding inhibitor in infancy: Relation to markers of adiposity and metabolic health

Authors
  • Diaz, Marta;
  • Blasco-Roset, Albert;
  • Villarroya, Joan;
  • Lopez-Bermejo, Abel;
  • de Zegher, Francis; 14217;
  • Villarroya, Francesc;
  • Ibanez, Lourdes;
Publication Date
May 20, 2021
Source
Lirias
Keywords
License
Unknown
External links

Abstract

BACKGROUND: Diazepam-binding inhibitor (DBI) controls feeding behaviour and glucose homeostasis. Individuals born small-for-gestational-age (SGA) with excessive postnatal catch-up in weight are at risk for obesity and type 2 diabetes. OBJECTIVE: To assess serum concentrations of DBI (0-2 years) in appropriate-for-gestational-age (AGA, n = 70) vs SGA infants (n = 33) with spontaneous catch-up and their relationship with endocrine-metabolic and adiposity markers. METHODS: Longitudinal assessments included auxology, fasting glucose, insulin, insulin-like growth factor, high-molecular-weight adiponectin, DBI and body composition (absorptiometry). DBI was measured cross-sectionally in pregnant and non-pregnant women and in 2-day-old newborns. DBI mRNA expression levels were assessed in adult and neonatal tissues. RESULTS: Cord blood DBI concentrations were similar in AGA and SGA newborns and about fivefold higher than those in women. Serum DBI levels decreased by age 2 days, were higher in SGA vs AGA infants at age 2 years and associated negatively with markers of adiposity and insulin resistance and positively with high-molecular-weight adiponectin. DBI mRNA expression was lower in placenta than in other tissues. CONCLUSION: The increased DBI concentrations at birth are unrelated to prenatal growth. The higher DBI levels in SGA subjects at age 2 years may be related to catch-up growth or represent an adaptive mechanism to promote lipogenesis. / status: published

Report this publication

Statistics

Seen <100 times